UPDATE: Tellabs Inc. (TLAB) CEO Rob Pullen Died of Cancer
Tweet
Share
E-mailGet Alerts TLAB Hot Sheet
Join SI Premium – FREE
(Updated - July 2, 2012 11:33 AM EDT)
Tellabs (Nasdaq: TLAB) CEO Rob Pullen died of cancer. Tellabs acting president and CEO Dan Kelly continues to lead Tellabs.
Below is a Letter from Chairman Mike Birck:
Dear Stockholders, Customers, Employees and Friends,
It is my sad duty to inform you that Tellabs CEO Rob Pullen has lost his battle with cancer. He passed away today.
We extend our sympathies to Rob's wife Dawn, his children Brittany and Brendan, and his family. Our thoughts and prayers are with them.
On a personal note, I was honored to have worked side by side with Rob at Tellabs for 30 years. No words can describe the grief I feel right now.
Tellabs acting president and CEO Dan Kelly continues to lead Tellabs.
Sincerely,
Michael J. BirckChairmanTellabs
Tellabs (Nasdaq: TLAB) CEO Rob Pullen died of cancer. Tellabs acting president and CEO Dan Kelly continues to lead Tellabs.
Below is a Letter from Chairman Mike Birck:
Dear Stockholders, Customers, Employees and Friends,
It is my sad duty to inform you that Tellabs CEO Rob Pullen has lost his battle with cancer. He passed away today.
We extend our sympathies to Rob's wife Dawn, his children Brittany and Brendan, and his family. Our thoughts and prayers are with them.
On a personal note, I was honored to have worked side by side with Rob at Tellabs for 30 years. No words can describe the grief I feel right now.
Tellabs acting president and CEO Dan Kelly continues to lead Tellabs.
Sincerely,
Michael J. BirckChairmanTellabs
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Waystar names new product chief and promotes commercial head
- Datavault AI gets 180-day Nasdaq compliance extension
- Akeso's ivonescimab beats durvalumab in biliary tract cancer trial
Create E-mail Alert Related Categories
Corporate News, Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
